Published in final edited form as:

Laryngoscope. 2018 March ; 128(3): 713–718. doi:10.1002/lary.26661.

An Adaptive Vestibular Rehabilitation Technique

Benjamin T. Crane, MD, PhD, FACS^{1,2,3} and Michael C. Schubert, PT, PhD^{4,5}

¹Department of Otolaryngology, University of Rochester

²Department of Neuroscience, University of Rochester

³Department of Bioengineering, University of Rochester

⁴Department of Otolaryngology, Johns Hopkins University

⁵Department of Physical Medicine and Rehabilitation, Johns Hopkins University

Abstract

Objectives—There is a large variation in vestibular rehabilitation (VR) results depending on type of therapy, adherence, and the appropriateness for the patient's level of function. A novel adaptive vestibular rehabilitation (AVR) program was developed and evaluated.

Study type—Technology and procedure development

Design—Prospective multi-center trial

Methods—Those with complete unilateral vestibular hypofunction (UVH) and symptomatic at least month with a dizziness handicap inventory (DHI)>30 were eligible. Patients were given a device to use with their own computer. They were instructed to use the program daily, with each session lasting about 10 minutes. The task consisted of reporting orientation of a letter C which appeared when their angular head velocity exceeded a threshold. The letter size and head velocity required were adjusted based on prior performance. Performance on the task was remotely collected by the investigator as well as a weekly DHI score.

Results—Four patients aged 31–74(mean 51) were enrolled in this feasibility study to demonstrate efficacy. Two had treated vestibular schwannomas and two had vestibular neuritis. Starting DHI was 32–56(mean 42) and reduced to 0–16(mean 11.5) after a month of therapy, a clinically and statistically significant ($p<0.05$) improvement. The three who continued therapy an additional month improved to a DHI of 4.

Conclusion—This AVR method has advantages over traditional VR in terms of cost and customization for patient ability and obtained a major improvement in symptoms. This study demonstrated a clinically and statistically significant decrease in symptoms after 4 weeks of therapy.

Corresponding author: Benjamin T. Crane, M.D., Ph.D., F.A.C.S., Associate Professor, 601 Elmwood Avenue, Department of Otolaryngology, Box 629, Rochester, NY 14642, craneb@gmail.com, Phone: 585-758-5700.

Conflict of interest: The authors have no conflicts of interest

Financial Disclosure: The first author as a patent on the technology described (Assignee is the University of Rochester). There are no other relevant financial relationships.

Level of evidence—2b**Keywords**

Vertigo; Human; Rehabilitation; Vestibular; Dizziness

Introduction

Unilateral vestibular hypofunction (UVH) is a common cause of dizziness and disequilibrium associated with head motion. The most common etiology is vestibular neuritis¹ which accounts for 7% of visits to vertigo clinics². Other etiologies include blast trauma³, neoplasms⁴, cholesteatoma, and iatrogenic causes.

Current treatment of UVH is limited and inadequate. Vestibular suppressants such as meclizine are commonly used but no better than a placebo⁵ and do not improve balance⁶. Steroids may accelerate recovery of vestibular neuritis^{7,8}, but offer no long term benefit⁹. Antiviral medications have been shown to have no effect⁸. The possibility for vestibular implants to replace lost peripheral vestibular function is being investigated^{10,11}, but use as a human therapy will likely be limited to patients with complete bilateral vestibular loss.

The mainstay of treatment for UVH is vestibular rehabilitation (VR). A recent review has found VR to be effective for improving dizziness, quality of life, and balance based on multiple randomized controlled trials¹². Recently, clinical practice guidelines have been established for VR¹³. VR exercises have been shown to significantly improve dynamic visual acuity (DVA)¹⁴ and dizziness handicap inventory (DHI)¹⁵ score^{16–18}. Despite benefits, there are significant limitations to the current VR techniques. When patients do VR independently at home, compliance (adherence) with therapy is unreported in most studies¹² but probably poor.

Another limitation is that patients probably do not do the technique properly. A typical adaptive VR technique based on gaze stabilization is to have the patient view a visible target while rotating their head side-to-side. However, head velocity should be at least 100°/s to ensure effective therapy¹⁹. Although face-to-face therapy with a trained therapist is effective, it is impractical because in many areas such therapists are not available, patients have limited time for these visits, and cost may be prohibitive for some patients. Evidence suggests 5 visits are needed to demonstrate a clinically significant improvement²⁰. However, outside of clinical studies it is likely that few patients attend more than 2 visits.

Multiple studies have shown patients with acute UVH who attended in-person VR therapy at least twice per week have a 57–66% DHI improvement^{16,18,21}. However, simply instructing patients to do exercises at home is much less effective with a DHI improvement of 10–27%^{17,22,23}. Although these small decreases are statistically significant, DHI must decrease by 18 points or 42% to be clinically significant²⁴.

The current study describes the development and testing of a web based adaptive vestibular rehabilitation (AVR) technique that patients do at home. The technique was designed to be able to individually monitor and adjust the therapy based on individual abilities as well as

monitor compliance similar to in-person VR but have low cost and convenience of home exercises. We demonstrate both the feasibility and efficacy of this approach.

Methods

Technology

Subjects were given a headset (Fig. 1) that included a small universal serial bus (USB) based device (Phidgets, Calgary, Alberta, Canada) containing 3 orthogonal gyros that measure rotational head velocity over the range of $\pm 2,000^\circ/\text{s}$ at a resolution of $0.1^\circ/\text{s}$ in pitch, yaw, and roll as well as linear accelerometers that cover the range of $\pm 8\text{ g}$ at a resolution of $< 1\text{ cm/s}^2$. The device had a standard USB port that allowed it to be connected to a standard personal computer (Windows or OS X) with a provided cable. Each headset had a unique, machine-readable serial number which allows the data collected to be associated with an individual without directly identification.

Participants used a webpage to participate with their headset plugged into an USB port on their computer (Fig. 2A). The first time they entered their screen size and viewing distance (Fig. 2B) allowing stimulus sizes to be calibrated. Next, they were brought to a menu which directed the patient to which tasks should be completed during that session (Fig 2C). The “therapy” task was highlighted at each visit while others such as “survey” were shown only when they were required (i.e. the DHI survey will be completed once per week). The therapy button brought subjects to an area where they were guided through a static visual acuity task followed by the adaptive dynamic task (Fig. 2D). Subjects were given appropriate directions for each task through the webpage. For the AVR task the head shown on the screen rotated at an appropriate frequency (0.8 Hz) and velocity and the optotype was only shown when a head velocity threshold was reached. The velocity threshold was set based on previous performance of between $80^\circ/\text{s}$ and $200^\circ/\text{s}$. Effective therapy requires a minimum velocity of $100^\circ/\text{s}$ ¹⁹. The starting velocity threshold was set at $80^\circ/\text{s}$ to allow subjects to gain experience and confidence with the technique without becoming frustrated and abandoning therapy early. It was our experience that most subjects made head movements with a peak velocity above $100^\circ/\text{s}$ when the minimum is set at $80^\circ/\text{s}$. Thus, the adaptive algorithm moved the threshold to above $100^\circ/\text{s}$ in the initial session. The size of the optotype was adjusted based on the speed and accuracy of prior responses.

Inclusion criteria

Subjects were eligible for the study if they were adults with a complete loss of unilateral vestibular function by caloric testing. In all 4 of the patients there was no caloric function on one side (including ice water calorics). Patients also needed to have had the lesion for at least 3 months and to have been symptomatic during this period such that the DHI was greater than 30 at the time of enrollment. The 3 month waiting period was used so that patients who were likely to experience a spontaneous recovery were not included. Patients also had to have an appropriate computer and internet access at home to participate.

Patients were excluded if they had Meniere’s disease by the American Academy of Otolaryngology criteria²⁵ with vertigo attacks in the past 3 months that had not been

definitively treated with either a labyrinthectomy or gentamicin. They were also excluded if they had symptoms that were exacerbated by computer use (common with vestibular migraine) and if they were currently engaged in any other vestibular therapy programs although prior participation did not disqualify. They were also excluded if they had a physical condition which would make them unable to participate (e.g. blindness, neck immobility, poor muscle control, etc.).

All patients completed a signed informed consent prior to participation. The protocol and consent forms were approved by the research science review board at the author's institution.

Human Subjects

Four patients (3 female) aged 31–74 (mean 51) were enrolled between December of 2011 and May of 2013. Two had treated vestibular schwannomas, one had vestibular neuritis, and one had labyrinthitis. By chance, all 4 had right-sided lesions. All 4 had a positive head thrust test²⁶ with rapid rotation towards the right. In one subject, the head thrust test was documented with quantitative eye movement recordings. Three that had cervical vestibular evoked myopotential (cVEMP) testing had absent responses on the right. Subject 1 was a 31 yo male who had a sudden onset of vestibular neuritis with no hearing loss 3 months prior to enrollment. Subject 2 was a 59 yo woman who had a 2.1 cm right sided vestibular schwannoma resected via a retrosigmoid approach 7 months prior to enrollment. Subject 3 was a 39 yo woman with a history of right labyrinthitis (idiopathic sudden unilateral loss of vestibular function and hearing) which occurred 17 months prior to enrollment. Subject 4 was a 74 year old woman who underwent gamma knife for a 1 cm right vestibular schwannoma 9 months prior to enrolling, and subsequently developed dizziness and imbalance 3 months prior to enrollment.

Three additional subjects met the enrollment criteria and agreed to participate but failed to complete more than one session. One subject dropped out due to technical issues with their computer. Two other subjects did not feel they had time for to participate. In two of the subjects no further clinical follow up was available. The 3rd represented in clinic a year later with similar symptom severity, she was offered the study again, agreed to participate, and again did not participate. Results from these subjects are not reported or considered further.

Protocol

Subjects were asked to complete the AVR task daily. This included logging into the system and completing 3 blocks of exercises. The first block was a static visual acuity task in which the subjects were instructed to keep their head still and report the orientation of the Landolt-C. This task was used as a control condition and was useful in measuring baseline visual acuity as well as the degree of performance improvement that could be attributed to repeating the task without any improvement in vestibular compensation. In the second and third block subjects oscillated their head from side-to-side and the optotype only appeared when a velocity threshold was reached in the rightward (block 2) or leftward (block 3) direction. In practice the direction specificity, was likely unnecessary as subjects generally made symmetric head oscillations. Prior to starting and on a weekly basis, subjects

completed the Jacobsen dizziness handicap inventory (DHI) ¹⁵ which was the primary outcome measure. Secondary outcomes measures included fraction of correct responses, time required to make responses, peak head velocity, and optotype size.

Results

All four subjects were able to complete 4 weeks of therapy. Of these initial subjects, 3 wished to continue for a total of 51–104 days. The mean DHI at the time of enrollment was 42 (range 32–56). After 4 weeks of therapy the DHI significantly (T-test, $p = 0.004$) decreased to 11.5 (range 0–16). In the 3 subjects who completed additional therapy, the DHI decreased significantly (T-test, $p = 0.002$) to 4 (range 2–6) relative to the pre-enrollment value at the end of therapy but was not significantly improved ($p = 0.3$) from the DHI at 4 weeks. This represents an average improvement of 30.5 points or 73% decrease at 4 weeks and 33.3 points or 90% decrease at 8 weeks. The performance on the AVR and DHI and DHI is shown for a typical subject (Fig. 3).

The performance of the static visual acuity (SVA) task did not improve over the course of the study. As shown in Fig. 3 the best performance remains stable at the equivalent of 20/16 and this was also typical of other participants. However the dynamic visual acuity (DVA) measures did improve over the course of the study similar to the DHI. This is consistent with most of the improvement in the DVA being due to recovery of gaze stability ²⁷, and not due to increased practice with the task itself. When the DVA task with ipsilesional rotation was compared with that of contralesional rotation, the acuity with contralesional rotation was on average twice as good as for ipsilesional rotation. However the difference was largest during the first 20 days when it was 2.6x better and smaller after 30 days. Thus the AVR task seems to preferentially improve vestibular function during ipsilesional rotation.

Despite the patients having a uniform improvement with the AVR task the compliance with the task was variable. Although all subjects were instructed to do the task every day only one subject (#4) had 100% compliance. Two subjects (#1 and #2) completed the task about every other day with compliance rates of 58% and 52% during the first month. The remaining subject (#3) did the task only about weekly, or 17% of the days during the first month. This suggests daily sessions may not be needed.

Discussion

The current study demonstrates a clinically and statistically significant improvement in the DHI for patients with UVH. This study enrolled only chronic UVH subjects to minimize potential effects of spontaneous improvement. Other studies of rehabilitation of chronic peripheral vestibular lesions using home based VR therapy ^{17,23,28} form a benchmark for evaluation of the current technique. Although these studies have demonstrated a statistically significant improvement with VR, the improvement was below the 18 point or 42% decrease proposed for clinical significance ²⁴. Although comparable improvement was described with acute lesions ^{16,29}, there is also a high rate of spontaneous recovery in acute lesions. The current results using the AVR technique are superior than those seen for home based therapy of chronic vestibular lesions and similar to those seen for in-person therapist directed VR

(Fig. 4), though with a small cohort. The reason for this is likely because the AVR technique adjusts the therapy to patient ability so that the exercises remain feasible to complete while challenging enough to be therapeutic.

A second major advantage of the current technique was that adherence to therapy was directly monitored. Compliance or adherence with therapy is rarely reported in studies of VR that patients complete independently¹². In a previous study of VR for Meniere's, compliance was found to be low at 50% in the control group and 38% in the treatment group²³. This measure was based on self reporting which is considered a low quality measure of compliance. Thus the compliance with VR was actually below the 43–78% range cited for compliance with medications in clinical trials³⁰. However, VR patients with good adherence to therapy had a significantly better outcome than those with poor adherence²³. The primary reason for poor compliance in that study was that the therapy aggravated symptoms²³. In previous medication compliance reports it has been shown that compliance rates in studies are better than in practice because of the additional attention paid to the patients³⁰. Thus compliance with unmonitored vestibular rehabilitation techniques in clinical practice is likely to be very poor, and compliance may explain the wide variation in outcomes between patients in some VR studies^{12,22,23,31}.

The compliance was extremely variable with 1 subject doing the AVR daily as directed, 2 doing it about every other day, and the remaining subject doing it only about weekly. In addition, two subjects whose data was not presented in the study did the task only one time and did not continue beyond the first week. Thus the overall compliance is probably near the 38% previously reported for patients with Meniere's²³. In the Yardley and Kirby study, which reported compliance, it was recommended that the exercises be completed daily, however other studies have recommended more frequent therapy at 3–5 times daily^{14,18,22,32}. Given that in the current study only one participant actually did the exercises daily as directed, expecting patients to do the exercises 3–5 times daily may be unrealistic, and given our preliminary yet strong results with once daily therapy, likely unnecessary.

The current AVR technique offered significant advantages. Although the efficacy appears similar to protocols that include 8–10 sessions with a therapist (Fig. 4) it allowed patients the convenience of therapy at home. The cost of hosting the web-based software is minimal so the AVR technology would be significantly cheaper than multiple visits with a therapist. It also has the advantage that adherence can be remotely monitored.

The current study had limitations. Subjects were not randomized so some degree of spontaneous improvement was possible, although only patients with chronic lesions were included to decrease this potential effect. The technique may have also had a placebo effect associated with it. There were also only a small number of patients enrolled in the current study which was largely due to the stringent entry criteria. However even with these small numbers the effect seen was highly statistically significant.

Conclusions

A novel home computer based AVR technique was tested in individuals with chronic complete UVD causing significant dizziness symptoms. In these patients 4 weeks of daily therapy significantly decreased the dizziness handicap by a mean of 71%. The majority of the benefit was seen in the first month of therapy.

Acknowledgments

Funding was provided by NIDCD R01 DC013580 and K23 DC011298 as well as a Triological Career Scientist Award. Technical support was provided by Kyle Critelli.

Bibliography

1. Baloh RW. Clinical practice. Vestibular neuritis. *N Engl J Med*. 2003; 348:1027–1032. [PubMed: 12637613]
2. Strupp M, Brandt T. Vestibular neuritis. *Semin Neurol*. 2009; 29:509–519. [PubMed: 19834862]
3. Scherer MR, Burrows H, Pinto R, et al. Evidence of central and peripheral vestibular pathology in blast-related traumatic brain injury. *Otol Neurotol*. 2011; 32:571–580. [PubMed: 21358450]
4. Humphriss RL, Baguley DM, Moffat DA. Change in dizziness handicap after vestibular schwannoma excision. *Otol Neurotol*. 2003; 24:661–665. [PubMed: 12851561]
5. Schmitt LG, Shaw JE. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine. *Arch Otolaryngol Head Neck Surg*. 1986; 112:88–91. [PubMed: 3940518]
6. Horak FB, Jones-Rycewicz C, Black FO, Shumway-Cook A. Effects of vestibular rehabilitation on dizziness and imbalance. *Otolaryngol Head Neck Surg*. 1992; 106:175–180. [PubMed: 1738550]
7. Walker MF. Treatment of vestibular neuritis. *Current treatment options in neurology*. 2009; 11:41–45. [PubMed: 19094835]
8. Strupp M, Zingler VC, Arbusow V, et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. *N Engl J Med*. 2004; 351:354–361. [PubMed: 15269315]
9. Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). *Cochrane Database Syst Rev*. 2011:CD008607. [PubMed: 21563170]
10. Rubinstein JT, Bierer S, Kaneko C, et al. Implantation of the semicircular canals with preservation of hearing and rotational sensitivity: a vestibular neurostimulator suitable for clinical research. *Otol Neurotol*. 2012; 33:789–796. [PubMed: 22699989]
11. Fridman GY, Della Santina CC. Progress toward development of a multichannel vestibular prosthesis for treatment of bilateral vestibular deficiency. *Anatomical record*. 2012; 295:2010–2029.
12. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. *Cochrane Database Syst Rev*. 2011:CD005397. [PubMed: 21328277]
13. Hall CD, Herdman SJ, Whitney SL, et al. Vestibular Rehabilitation for Peripheral Vestibular Hypofunction: An Evidence-Based Clinical Practice Guideline: FROM THE AMERICAN PHYSICAL THERAPY ASSOCIATION NEUROLOGY SECTION. *Journal of neurologic physical therapy : JNPT*. 2016; 40:124–155. [PubMed: 26913496]
14. Herdman SJ, Schubert MC, Das VE, Tusa RJ. Recovery of dynamic visual acuity in unilateral vestibular hypofunction. *Arch Otolaryngol Head Neck Surg*. 2003; 129:819–824. [PubMed: 12925338]
15. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. *Arch Otolaryngol Head Neck Surg*. 1990; 116:424–427. [PubMed: 2317323]
16. Teggi R, Caldirola D, Fabiano B, Recanati P, Bussi M. Rehabilitation after acute vestibular disorders. *J Laryngol Otol*. 2009; 123:397–402. [PubMed: 18549515]

17. Yardley L, Donovan-Hall M, Smith HE, Walsh BM, Mullee M, Bronstein AM. Effectiveness of primary care-based vestibular rehabilitation for chronic dizziness. *Ann Intern Med.* 2004; 141:598–605. [PubMed: 15492339]
18. Giray M, Kirazli Y, Karapolat H, Celebisoy N, Bilgen C, Kirazli T. Short-term effects of vestibular rehabilitation in patients with chronic unilateral vestibular dysfunction: a randomized controlled study. *Archives of physical medicine and rehabilitation.* 2009; 90:1325–1331. [PubMed: 19651266]
19. Schubert MC, Minor LB. Vestibulo-ocular physiology underlying vestibular hypofunction. *Phys Ther.* 2004; 84:373–385. [PubMed: 15049730]
20. Rossi-Izquierdo M, Santos-Perez S, Rubio-Rodriguez JP, et al. What is the optimal number of treatment sessions of vestibular rehabilitation? *Eur Arch Otorhinolaryngol.* 2013
21. Topuz O, Topuz B, Ardic FN, Sarhus M, Ogmen G, Ardic F. Efficacy of vestibular rehabilitation on chronic unilateral vestibular dysfunction. *Clinical rehabilitation.* 2004; 18:76–83. [PubMed: 14763722]
22. Cohen HS, Kimball KT. Increased independence and decreased vertigo after vestibular rehabilitation. *Otolaryngol Head Neck Surg.* 2003; 128:60–70. [PubMed: 12574761]
23. Yardley L, Kirby S. Evaluation of booklet-based self-management of symptoms in Meniere disease: a randomized controlled trial. *Psychosomatic medicine.* 2006; 68:762–769. [PubMed: 17012531]
24. Clendaniel, R., Goode, A. Measurement properties of the dizziness handicap inventory. APTA combined sections meeting; San Diego, CA. 2013;
25. Committee on hearing and equilibrium. Guidelines for the diagnosis and evaluation of therapy in Meniere's disease. *Otolaryngol Head Neck Surg.* 1996; 114:236–241.
26. Halmagyi GM, Curthoys IS. A clinical sign of canal paresis. *Arch Neurol.* 1988; 45:737–739. [PubMed: 3390028]
27. Schubert MC, Migliaccio AA, Clendaniel RA, Allak A, Carey JP. Mechanism of dynamic visual acuity recovery with vestibular rehabilitation. *Archives of physical medicine and rehabilitation.* 2008; 89:500–507. [PubMed: 18295629]
28. Cohen B, Dai M, Raphan T. The critical role of velocity storage in production of motion sickness. *Ann N Y Acad Sci.* 2003; 1004:359–376. [PubMed: 14662476]
29. Enticott JC, O'Leary SJ, Briggs RJ. Effects of vestibulo-ocular reflex exercises on vestibular compensation after vestibular schwannoma surgery. *Otol Neurotol.* 2005; 26:265–269. [PubMed: 15793417]
30. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med.* 2005; 353:487–497. [PubMed: 16079372]
31. Herdman SJ. Vestibular rehabilitation. *Curr Opin Neurol.* 2012
32. Herdman SJ, Hall CD, Delaune W. Variables associated with outcome in patients with unilateral vestibular hypofunction. *Neurorehabilitation and neural repair.* 2012; 26:151–162. [PubMed: 21959673]

Figure 1.

The headset given to participants to complete either the AVR. The headset is adjustable to a range of head sizes using a ratchet and has a 6 foot USB cable to allow the subject to sit an appropriate distance from their computer screen. The headset has a sticker which tells the subject the website they should visit and a number to call if they need technical support. The system gave the user some feedback to provide motivation such as showing the size of the optotype and revealing the fraction of correct responses at the end of a trial block. For each response entered the data collected on the server included the time required, the orientation and size of the optotype, the accuracy of the response, the recent history of head movements, and information regarding the performance of the subject's computer.

Figure 2.

Sample screen images from the computer based task. A. Introductory screen that the participant sees when first visiting the website. B. Subjects are prompted to enter some set up information at the first visit which includes the size of their computer screen and the distance they are sitting. This can be updated as needed. C. A menu directs subjects to potential tasks, marking the ones expected to be completed during that visit. D. The “therapy” button brings up either the adaptive vestibular rehabilitation task or a placebo. Although the image shows the rehabilitation task the placebo looks similar.

Figure 3.

Sample data from subject 2 (59 yo woman with a history of chronic right sided UVH). This subject participated in the AVR program for 3 months. Each session consisted of static visual acuity, followed by a left and then right DVA task. The acuity is given as the denominator on a Snellen scale based on a 20 foot viewing distance, although the viewing distance was less than 20 ft. The performance on the DVA task (panel A) was correlated with the DHI (panel B).

Figure 4. Historical data and current results for pre- and post-treatment DHI using various VR protocols. The method of VR varied with some relying on patients doing the therapy independently and others focused on in-person sessions with a therapist. Datasets which met the criteria for a minimal clinically important response (either 18 points or a 42% decrease in DHI) are marked with an asterisk ²⁴. In the prior studies, only in-person VR sessions were able to meet this threshold. All of the studies shown except Teggi et al. (2009), only included patients with symptoms present for 2 months or longer. The current data (furthest right column) demonstrates the AVR method has a similar large decrease in DHI in home based therapy.